SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.998
AS - Asia 7.312
EU - Europa 4.053
SA - Sud America 999
Continente sconosciuto - Info sul continente non disponibili 222
AF - Africa 152
OC - Oceania 15
Totale 27.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.625
SG - Singapore 2.705
CN - Cina 1.835
VN - Vietnam 862
DE - Germania 794
BR - Brasile 763
IT - Italia 661
UA - Ucraina 639
HK - Hong Kong 518
GB - Regno Unito 466
TR - Turchia 434
FI - Finlandia 416
FR - Francia 261
BD - Bangladesh 239
CA - Canada 195
SE - Svezia 188
JP - Giappone 184
RU - Federazione Russa 159
IN - India 146
MX - Messico 123
PL - Polonia 119
ID - Indonesia 107
AR - Argentina 89
AT - Austria 72
ZA - Sudafrica 61
ES - Italia 56
NL - Olanda 55
BE - Belgio 52
PK - Pakistan 50
IQ - Iraq 47
EC - Ecuador 34
CO - Colombia 31
VE - Venezuela 30
LT - Lituania 28
PH - Filippine 22
MA - Marocco 21
MY - Malesia 19
UZ - Uzbekistan 19
SA - Arabia Saudita 18
EG - Egitto 17
PE - Perù 16
KE - Kenya 15
CL - Cile 14
AE - Emirati Arabi Uniti 13
AU - Australia 13
CZ - Repubblica Ceca 13
JO - Giordania 13
CR - Costa Rica 11
IR - Iran 11
CH - Svizzera 9
NO - Norvegia 9
NP - Nepal 9
BG - Bulgaria 8
BO - Bolivia 8
ET - Etiopia 8
IE - Irlanda 8
JM - Giamaica 8
PY - Paraguay 8
TN - Tunisia 8
AZ - Azerbaigian 7
DZ - Algeria 7
HN - Honduras 7
IL - Israele 7
PA - Panama 7
AL - Albania 6
KG - Kirghizistan 6
KZ - Kazakistan 6
PS - Palestinian Territory 5
RO - Romania 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
LV - Lettonia 4
PT - Portogallo 4
UY - Uruguay 4
BW - Botswana 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
KR - Corea 3
LY - Libia 3
NI - Nicaragua 3
OM - Oman 3
RS - Serbia 3
CG - Congo 2
DM - Dominica 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
KH - Cambogia 2
LK - Sri Lanka 2
MT - Malta 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
Totale 27.507
Salva come PNG Salva come JPEG
Città #
Ashburn 1.897
Singapore 1.764
Fairfield 1.266
Woodbridge 1.234
San Jose 1.145
Houston 705
Beijing 679
Jacksonville 674
Chandler 666
Santa Clara 624
Ann Arbor 517
Hong Kong 508
Seattle 487
Wilmington 450
Cambridge 416
Munich 365
Council Bluffs 291
Dallas 284
Ho Chi Minh City 259
Izmir 239
Los Angeles 221
New York 220
Helsinki 211
Hanoi 205
Tokyo 175
Nanjing 173
Ferrara 171
Princeton 167
Lauterbourg 131
San Diego 115
Warsaw 109
Shanghai 107
Boardman 105
Milan 104
São Paulo 79
Jakarta 76
London 71
Mexico City 69
Bremen 66
Orem 64
Toronto 62
Turku 58
Buffalo 57
Shenyang 57
Brooklyn 53
Tianjin 51
Brussels 50
Chicago 50
Da Nang 49
Falls Church 48
Montreal 48
The Dalles 48
Atlanta 46
Hebei 45
Hefei 45
Vienna 45
Moscow 44
Frankfurt am Main 43
Denver 42
Boston 39
Nanchang 38
Haiphong 35
Chennai 34
Stockholm 34
Johannesburg 33
Manchester 32
Phoenix 32
Changsha 31
Norwalk 30
Jiaxing 29
Poplar 29
San Francisco 27
Washington 27
Biên Hòa 26
Rome 26
Rio de Janeiro 25
San Mateo 25
Ankara 24
Auburn Hills 24
Amsterdam 22
Jinan 22
Mountain View 22
Falkenstein 21
Ottawa 21
New Delhi 20
Redwood City 20
Guangzhou 19
Baghdad 18
Belo Horizonte 18
Brasília 18
Charlotte 18
Dearborn 18
Mumbai 18
Tashkent 17
Zhengzhou 17
Istanbul 16
Nuremberg 16
Querétaro 16
Lahore 15
Lappeenranta 14
Totale 19.036
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 398
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 380
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 330
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 311
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 285
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 284
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 277
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 274
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 274
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 269
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 266
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 264
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 260
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 244
5‐Hydroxytryptamine‐mediated effects of nicotine on endogenous GABA efflux from guinea‐pig cortical slices 243
Antagonisti dei recettori NOP e loro usi terapeutici 239
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 239
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 238
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 232
Loss of cortical GABA terminals in Unverricht–Lundborg disease 231
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 231
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 231
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 231
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 227
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 225
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 225
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 224
Autophagy and LRRK2 in the Aging Brain 220
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 219
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 219
Role of LRRK2 in the regulation of dopamine receptor trafficking 219
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 219
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 218
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]‐d‐aspartate and endogenous GABA in freely moving guinea‐pigs 218
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 217
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 217
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 217
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 217
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 212
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 212
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 208
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 207
NOP receptor ligands and Parkinson’s disease 207
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 206
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 206
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 204
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 203
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 202
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 201
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 200
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 200
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 199
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 199
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 196
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 195
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 194
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 193
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 191
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 189
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 189
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 189
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 188
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 187
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 186
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 186
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 184
Parkinson's disease: no NOP, new hope 182
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 182
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 178
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 174
Managing Parkinson's disease: moving ON with NOP 172
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 171
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 168
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 168
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 166
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter 166
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 165
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 165
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 164
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat 163
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 162
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 162
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 162
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity 161
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 159
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 159
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 158
Nociceptin/orphanin FQ receptor antagonists reverse parkinsonism in MPTP-treated mice and non-human primates 157
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 157
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice 157
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 156
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 154
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 152
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 151
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 149
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease 149
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 146
Differential regulation of striato-nigral and striato-pallidal pathways by striatal NR2A and NR2B subunit containing receptors 145
Comparison of 3H-choline and 3H-aspartate efflux from guinea-pig and human neocortex 144
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia 144
Totale 20.533
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.036
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.607
Totale 127.643
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.509 0 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/20253.708 74 88 310 82 402 505 146 204 569 373 528 427
2025/202611.039 1.178 343 893 1.354 1.681 739 1.415 556 979 1.198 465 238
2026/2027460 239 221 0 0 0 0 0 0 0 0 0 0
Totale 27.751